Received Jul 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | UNK | — |
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Fetal exposure during pregnancy; infant was diagnosed with a capillary hemangioma; This serious retrospective pregnancy case was reported by a other health professional and described the occurrence of capillary hemangioma in a female child exposed to DTPa (Reduced antigen) (Boostrix) solution for injection (batch number 25A2F) in utero. The mother received the product for prophylaxis. The parent's medical history included alcohol use, anxiety (in 2022), coronavirus infection, migraine (in 2017), allergy (Injected 0.5 shot,1.5 month), augmentin (1 pill orally every 2 days), claritin (10 mg oral once day), docusate (100 mg Oral one week), flonase (2 puffs intranasally for 3.5 weeks), guaifenesin (400 mg orally, total of 3 doses), miralax (Oral), pfizer biontech covid-19 vaccine (intramuscular 1 shot,1 day), prenatal vitamin (1 pill orally every 1 days), sertraline hcl (50 mg oral once day), sinus (08-MAR-2023 to 22-MAR-2023), tums (oral 3 pill,5 week), tylenol (500 mg oral 2 month), tylenol (500 mg oral once day), tylenol (oral 1 pill,5.5 total) and Gravidity: 1 Parity: 0 Spontaneous Abortion: 0 Theraputic Abortion: 0. On 12-OCT-2023, the mother received Boostrix (intramuscular). On 31-OCT-2023, the mother received RSV vaccine. On 04-OCT-2023, the mother received Flu vaccine. On 25-SEP-2023, the mother received PFIZER BIONTECH COVID-19 VACCINE. The child was diagnosed with capillary hemangioma (Verbatim: infant was diagnosed with a capillary hemangioma) (serious criteria congenital anomaly). On an unknown date, the child experienced fetal exposure during pregnancy (Verbatim: Fetal exposure during pregnancy). The outcome of the capillary hemangioma was not reported and the outcome of the fetal exposure during pregnancy was not applicable. It was unknown if the reporter considered the capillary hemangioma to be related to Boostrix, RSV vaccine and Flu vaccine. The company considered the capillary hemangioma to be unrelated to Boostrix, RSV vaccine and Flu vaccine. Pregnancy exposure: Gestation time at first exposure (Boostrix): 31 Weeks Pregnancy Exposure (Boostrix): To foetus directly in utero Gestation time at first exposure (RSV vaccine): 33 Weeks Gestation time at first exposure (PFIZER BIONTECH COVID-19 VACCINE): 28 Weeks Last Menstrual Period Date: 09-MAR-2023 Estimated Delivery/Due date: 10-DEC-2023 Pregnancy Details (Neonate 1): Actual Delivery Date: Gestation Time at Delivery: 39 weeks and 3 days Delivery Type: vaginal Pregnancy Outcome: Live neonate with a congenital anomaly Birth Weight: 3198 grams (7lbs 1oz) Apgar Scores: 7 and 8 Delivery Notes: Female baby with birth weight 3198 gm, birth length 50.8 cm, birth head circumference 34.5 Additional Information: GSK Receipt Date: 22-JUL-2026 The mother of the patient mentioned she enrolled prospectively in the study with pregnancy exposed to Boostrix. The mother delivered a liveborn infant. On 10-Dec-2023, the infant was diagnosed with capillary hemangioma.; Sender's Comments: A case of Haemangioma of skin female child, 40 days after vaccination with unknown doses of Boostrix, RSV vaccine and Flu vaccine, in a mother patient. Causal relation is indeterminate considering multiple vaccines given.